328 related articles for article (PubMed ID: 19817870)
1. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.
Steckelings UM; Rompe F; Kaschina E; Unger T
Fundam Clin Pharmacol; 2009 Dec; 23(6):693-703. PubMed ID: 19817870
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
Bilous R
Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
[No Abstract] [Full Text] [Related]
4. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin system and diabetic nephropathy.
Gurley SB; Coffman TM
Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
[TBL] [Abstract][Full Text] [Related]
6. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
7. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
8. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
9. Role of angiotensin II in diabetic nephropathy.
Kennefick TM; Anderson S
Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
[TBL] [Abstract][Full Text] [Related]
10. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the renin-angiotensin system and target organ protection.
Iwanami J; Mogi M; Iwai M; Horiuchi M
Hypertens Res; 2009 Apr; 32(4):229-37. PubMed ID: 19262496
[TBL] [Abstract][Full Text] [Related]
12. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
13. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
Strawn WB
Drugs; 2002; 62 Spec No 1():31-41. PubMed ID: 12036387
[TBL] [Abstract][Full Text] [Related]
14. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
Cooper ME
Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms for the clinical benefits of angiotensin II receptor blockers.
Schmieder RE
Am J Hypertens; 2005 May; 18(5 Pt 1):720-30. PubMed ID: 15882557
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor blockers: novel role in high-risk patients.
Javed U; Deedwania PC
Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
[TBL] [Abstract][Full Text] [Related]
17. Hypertension and diabetes: role of the renin-angiotensin system.
Jandeleit-Dahm K; Cooper ME
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
19. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
20. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
